Literature DB >> 3115785

Bone metastases in primary operable breast cancer. The role of a yearly scintigraphy.

H S Thomsen1, D Rasmussen, O Munck, J O Lund, V Gerhard-Nielsen, T Terkildsen, P Dombernowsky, K W Andersen.   

Abstract

In 231 patients with primary operable breast cancer bone scintigraphies were performed yearly from the second to the 6th year until recurrence irrespective of localization was diagnosed, another cancer was detected, or the patient refused further follow-up or died. During the observation period (from 2 up to 7 years after surgery) 13 patients (5.6%) had bone metastases verified by X-ray or histology within 12 months after the last bone scintigraphy. The scintigraphy was positive in only 7 of these patients. The yearly incidence of bone metastases varied between 0.6 and 2.6%. Due to this low incidence and a low cost/benefit, we conclude that a fixed schedule of repeated scintigraphies in primary operable breast cancer patients otherwise free of apparent disease is not justified.

Entities:  

Mesh:

Year:  1987        PMID: 3115785     DOI: 10.1016/0277-5379(87)90278-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  4 in total

1.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Value of bone scanning in the follow-up of breast cancer patients. A study of 1000 cases.

Authors:  H Schünemann; P J Langecker; W Ellgas; A Leonhardt; H Merkl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer.

Authors:  M S Simon; M Stano; M Hussein; M Hoff; D Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.

Authors:  M S Simon; M Hoff; M Hussein; S Martino; A Walt
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.